.Attribute Medication, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of individuals along with HER2+ advanced bosom cancer cells and energetic or steady mind metastases revealed regular intracranial task and systemic effectiveness of T-DXd.